Clinical approach to lung diseases in HIV-infected patients (review)
https://doi.org/10.22625/2072-6732-2020-12-2-12-18
Abstract
The review presents literature data on therapeutic and diagnostic management of pulmonary diseases in HIV-infected patients. The article provides different practical approaches in the diagnosis of HIV-associated lung lesions and the spectrum of probable diseases, depending on the degree of immunodeficiency and the severity of clinical manifestations. The reference clinical signs of the most common opportunistic diseases with possible lung involvement are presented.
The literature review highlights the feasibility of accurate etiological and invasive diagnosis of lung lesions in different clinical settings, as well as the need to designate various options of empirical antimicrobial therapy. The features of antimicrobial therapy and, in particular, the use of fluoroquinolones during the differential diagnosis of pulmonary lesions in HIV infection are discussed. The difficulties of verifying of HIV-associated lung diseases indicate the need of unified therapeutic and diagnostic approaches for use by various physicians (general practitioners, pulmonologists and
phthisiologists).
The literature review highlights the feasibility of accurate etiological and invasive diagnosis of lung lesions in different clinical settings, as well as the need to designate various options of empirical antimicrobial therapy. The features of antimicrobial therapy and, in particular, the use of fluoroquinolones during the differential diagnosis of pulmonary lesions in HIV infection are discussed. The difficulties of verifying of HIV-associated lung diseases indicate the need of unified therapeutic and diagnostic approaches for use by various physicians (general practitioners, pulmonologists and
phthisiologists).
About the Authors
I. B. Viktorova
Novokuznetsk State Institute for Further Training of Physicians – Branch Campus of Russian Medical Academy of Continuous Professional Education
Russian Federation
Novokuznetsk
Russian Federation
Novokuznetsk
V. N. Zimina
Peoples’ Friendship University of Russia
Russian Federation
Moscow
Russian Federation
Moscow
S. Yu. Degtyareva
Peoples’ Friendship University of Russia
Russian Federation
Moscow
Russian Federation
Moscow
A. V. Kravtchenko
Сentral Research Institute of Epidemiology
Russian Federation
Moscow
Russian Federation
Moscow
References
1. Kalacheva G.A. Analiticheskij obzor epidemii VICH-infekcii v Sibirskom federal’nom okruge v 2014 g: monografiya / Kalacheva G.A., Tyumencev A.T., Dovgopolyuk E.S. – Omsk: ООО Izdatel’skij centr «Omskij nauchnyj vestnik», 2015. – 31 p. (in Russian).
2. Ermak T.N. Analiz prichin letal’nyh iskhodov bol’nyh VICH-infekciej v Rossijskoj Federacii / Ermak T.N., Kravchenko A.V., Shakhgil’dian V.I. // Infekcionnye bolezni. – 2010. – № 3. – p. 19–20. (in Russian).
3. Kozhevnikova G.M., Voznesenskiy S.L., Ermak T.N., Smetanina S.V., Petrova E.V., Samotolkina E.A. Prognostic factors of a favourable outcome of treating HIV-infected patients in an intensive care unit. Infekc. bolezni (Infectious diseases). 2017; 15(3): 20–24. (In Russian).
4. Tyutrina V.D. VICH-inficirovannye pacienty v mnogoprofil’noj bol’nice / Tyutrina V.D., Bayanova T.A., Botvinkin A.D., Makarova K.A., Talikina T.O., Khagdaeva E.G. // Medicina v Kuzbasse. – 2013. – N2. – S. 74–8. (in Russian).
5. Evstigneev I.V. Legochnaya patologiya u VICH-inficirovannyh v praktike terapevta / Evstigneev I.V., Makhova I.B., Vasilenko P.I., Grishnyakova A.A., Yarchenko L.I.. Maksimovich T.I. // Ukrainskij terapevtichnij zhurnal. – 2011. – №1. – S. 70–75. (in Russian).
6. Sarkar P, Rasheed HF. Clinical review: Respiratory failure in HIV-infected patients--a changing picture. Crit Care. 2013 Jun;17(3):228.
7. Ladnaya N.N. Razvitie epidemii VICH-infekcii v Rossijskoj Federacii v 2015 g / Ladnaya N.N., Pokrovsky V.V., Dement’yeva L.A., Simashev T.N., Lipina E.S., Yurin O.G. // Materialy nauchno-prakticheskoj konferencii «Aktual’nye voprosy VICH-infekcii». – SPb: OOO «CHelovek i ego zdorov’e», 2016. – S. 4–9. (in Russian).
8. Pokrovsky V.V. Infekciya, vyzyvaemaya virusom immunodeficita cheloveka, v Rossii / Pokrovsky V.V. // Terapevtecheskij arhiv. – 2016. – №88 Т.11. – S. 4–11. (in Russian).
9. Ermak T.N. pportunisticheskie (vtorichnye) zabolevaniya u bol’nyh VICH–infekciej v Rossijskoj Federacii: struktura, klinicheskaya diagnostika, lechenie. CHast’ 1.
10. Tuberkulez i pnevmocistnaya pnevmoniya / Ermak T.N. // Farmateka. – 2010. – 4. – S. 52–56. (in Russian).
11. Babaeva I.Yu. Patomorfologicheskei osobennosti tuberkuleza legkih na raznyh stadiyah VICH-infekcii (po dannym autopsii) / Babaeva I.Yu., Zemskova Z.S., Gedimin L.E. // Problemy tuberkuleza. – 2007 . – 12. – S. 38–41. (in Russian).
12. Parkhomenko Yu.G. Differencial’naya diagnostika destruktivnyh porazhenij legkih pri VICH-associirovannyh infekciyah / Parkhomenko Yu.G., Zyuzya Yu.R., Fligil’ D.M. // Arhiv patologii. – 2011. – 1. – S. 9–12. (in Russian).
13. Narayanswami G, Salzman SH. Bronchoscopy in the human immunodeficiency virus-infected patient. Semin Respir Infect. 2003 Jun;18(2):80–6.
14. Benito N, Rañó A, Moreno A, González J, Luna M, Agustí C, et al. Pulmonary Infiltrates in HIV-Infected Patients in the Highly Active Antiretroviral Therapy Era in Spain. JAIDS J Acquir Immune Defic Syndr [Internet]. 2001;27:35–43. Available from: https://journals.lww.com/jaids/Fulltext/2001/05010/Pulmonary_Infiltrates_in_HIV_Infected_Patients_in.6.aspx
15. Tu J V, Biem HJ, Detsky AS. Bronchoscopy versus empirical therapy in HIV-infected patients with presumptive Pneumocystis carinii pneumonia. A decision analysis. Am Rev Respir Dis. 1993 Aug;148(2):370–7.
16. Puzireva L.V. Zabolevaniya organov dyhaniya pri VICH-infekcii (obzor) / Puzireva L.V., Safonov A.D., Mordik A.V. // Zhurnal infektologii – 2016. – №8 Т. 2. – S. 17–25. (in Russian).
17. Murray JF. Pulmonary complications of HIV-1 infection among adults living in Sub-Saharan Africa. Int J Tuberc Lung Dis. 2005 Aug;9(8):826–35.
18. Walusimbi S, Semitala F, Bwanga F, Haile M, De Costa A, Davis L, et al. Outcomes of a clinical diagnostic algorithm for management of ambulatory smear and Xpert MTB/Rif negative HIV infected patients with presumptive pulmonary TB in Uganda: a prospective study. Pan Afr Med J [Internet]. 2016 Mar 31;23:154. Available from: https://www.ncbi.nlm.nih.gov/pubmed/27303572
19. Schleenvoigt BT, Rupp J, Rohde G, Rockstroh JK, Fatkenheuer G, Pletz MW. Strategies for the Treatment of Community-Acquired Pneumonia in HIV-Positive Patients. Pneumologie. 2017 Apr;71(4):207–14.
20. WHO. Improving the diagnosis and treatment of smearnegative pulmonary and extrapulmonary tuberculosis among adults and adolescents: Recommendations for HIV-prevalent and resource-constrained settings. [Internet]. 2007. [cited 2019 Sep 4]. Available from:https://apps.who.int/iris/bitstream/handle/10665/69463/WHO_HTM_TB_2007.379_eng.pdf?sequence=1
21. Lawn SD, Ayles H, Egwaga S, Williams B, Mukadi YD, Santos Filho ED, et al. Potential utility of empirical tuberculosis treatment for HIV-infected patients with advanced immunodeficiency in high TB-HIV burden settings. Int J Tuberc Lung Dis. 2011 Mar;15(3):287–95.
22. Katagira W, Walter ND, Den Boon S, Kalema N, Ayakaka I, Vittinghoff E, et al. Empiric TB Treatment of Severely Ill Patients With HIV and Presumed Pulmonary TB Improves Survival. J Acquir Immune Defic Syndr. 2016 Jul;72(3):297–303.
23. Schleicher GK, Hopley MJ, Feldman C. CD4 T-lymphocyte subset counts in HIV-seropositive patients during the course of community-acquired pneumonia caused by Streptococcus pneumoniae. Clin Microbiol Infect. 2004 Jun;10(6):587–9.
24. Ferrand H, Crockett F, Naccache J-M, Rioux C, Mayaud C, Yazdanpanah Y, et al. Pulmonary manifestations in HIVinfected patients: a diagnostic approach. Rev Mal Respir. 2014 Dec;31(10):903–15.
25. Gallant JE, Ko AH. Cavitary pulmonary lesions in patients infected with human immunodeficiency virus. Clin Infect Dis. 1996 Apr;22(4):671–82.
26. Allen CM, Al-Jahdali HH, Irion KL, Al Ghanem S, Gouda A KA. Imaging lung manifestations of HIV/AIDS. Ann Thorac Med. 2010;5(4):201–16.
27. Boiselle PM, Tocino I, Hooley RJ, Pumerantz AS, Selwyn PA, Neklesa VP, et al. Chest radiograph interpretation of Pneumocystis carinii pneumonia, bacterial pneumonia, and pulmonary tuberculosis in HIV-positive patients: accuracy, distinguishing features, and mimics. J Thorac Imaging. 1997 Jan;12(1):47–53.
28. Marchiori E, Muller NL, Soares Souza AJ, Escuissato DL, Gasparetto EL, Franquet T. Pulmonary disease in patients with AIDS: high-resolution CT and pathologic findings. AJR Am J Roentgenol. 2005 Mar;184(3):757–64.
29. Mathur M, Badhan RK, Kumari S, Kaur N, Gupta S. Radiological Manifestations of Pulmonary Tuberculosis – A Comparative Study between Immunocompromised and Immunocompetent Patients. J Clin Diagn Res. 2017 Sep;11(9):TC06–9.
30. Kim B, Kim J, Paik SS, Pai H. Atypical Presentation of Pneumocystis jirovecii Infection in HIV Infected Patients: Three Different Manifestations. Vol. 33, Journal of Korean medical science. Korea (South); 2018. p. e115.
31. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medical Association of the [Internet]. 2019 [cited 2019 Jul 15]. p. 423. Available from: http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf. Accessed 5/24/2019.
32. Viktorova I.B. Disseminirovannye zabolevaniya legkih u pacientov s razlichnym VICH-statusom: uchebnoe posobie v algoritmah / Viktorova I.B., Zimina V.N., Kravchenko A.V., Khanin A.L. – М.: GEOTAR-Media, 2017. – 248 p. (in Russian).
33. Fox GJ, Benedetti A, Cox H, Koh W-J, Viiklepp P, Ahuja S, et al. Group 5 drugs for multidrug-resistant tuberculosis: individual patient data meta-analysis. Eur Respir J. 2017 Jan;49(1).
34. WHO. WHO consolidated guidelines on drug-resistant tuberculosis treatment. [Internet]. 2019 [cited 2019 Sep 8]. p.99. Available from: https://apps.who.int/iris/bitstream/handle/10665/311389/9789241550529-eng.pdf?ua=1
35. Viktorova I.B. Bakteriovydelenie u pacientov s VICHinfekciej i tuberkulezom / Viktorova I.B., Zimina V.N., Kravchenko A.V., Khanin A.L. // Epidemiologiya i infekcionnye bolezni. Aktual’nye voprosy. – 2018. – T. 3. – S. 35–40. (in Russian).
36. van der Heijden YF, Maruri F, Blackman A, Mitchel E, Bian A, Shintani AK, et al. Fluoroquinolone susceptibility in Mycobacterium tuberculosis after pre-diagnosis exposure to olderversus newer-generation fluoroquinolones. Int J Antimicrob Agents [Internet]. 2013/06/24. 2013 Sep;42(3):232–7. Available from: https://www.ncbi.nlm.nih.gov/pubmed/23806638
37. Devasia RA, Blackman A, Gebretsadik T, Griffin M, Shintani A, May C, et al. Fluoroquinolone resistance in Mycobacterium tuberculosis: the effect of duration and timing of fluoroquinolone exposure. Am J Respir Crit Care Med. 2009 Aug;180(4):365–70.
38. Migliori GB, Langendam MW, D’Ambrosio L, Centis R, Blasi F, Huitric E, et al. Protecting the tuberculosis drug pipeline: stating the case for the rational use of fluoroquinolones. Eur Respir J. 2012 Oct;40(4):814–22.
39. Chen T-C, Lu P-L, Lin C-Y, Lin W-R, Chen Y-H. Fluoroquinolones are associated with delayed treatment and resistance in tuberculosis: a systematic review and meta-analysis. Int J Infect Dis. 2011 Mar;15(3):e211-6.
Review
For citations:
Viktorova I.B., Zimina V.N., Degtyareva S.Yu., Kravtchenko A.V. Clinical approach to lung diseases in HIV-infected patients (review). Journal Infectology. 2020;12(2):12-18. (In Russ.) https://doi.org/10.22625/2072-6732-2020-12-2-12-18
Views:
660
.png)
.png)
Email this article 